Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V) (PnPS 9V)

The Streptococcus pneumoniae capsular polysaccharide serotype 9V is a complex carbohydrate polymer that forms the outermost protective layer of the bacterium, serving as a primary virulence factor (Geno et al., 2015). This polysaccharide structure is essential for the pathogen's survival within the host, as it physically masks underlying surface antigens and inhibits opsonization by complement proteins and antibodies, thereby preventing phagocytosis by host immune cells (CDC, 2022). Serotype 9V is clinically significant due to its frequent association with invasive pneumococcal diseases such as meningitis, bacteremia, and pneumonia, particularly in pediatric and elderly populations (Hausdorff et al., 2000). Furthermore, strains belonging to serotype 9V have historically demonstrated high levels of resistance to penicillin and other beta-lactam antibiotics, complicating treatment efforts (CDC, 2022). As a therapeutic target, this polysaccharide is included as a purified antigen in the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and as a protein-conjugated antigen in several pneumococcal conjugate vaccines, including PCV13, PCV15, and PCV20 (FDA, 2021). These vaccines function by inducing a T-cell independent or T-cell dependent humoral immune response, resulting in the production of serotype-specific IgG antibodies that facilitate the clearance of the bacteria through opsonophagocytosis.

Other names

Pneumococcal polysaccharide serotype 9VS. pneumoniae type 9V capsular polysaccharideCPS 9VStreptococcus pneumoniae serotype 9V antigenType 9V pneumococcal polysaccharide

Induction of active immunity through the production of serotype-specific antibodies that promote opsonophagocytosis and neutralization of the bacteria.